New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended
ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.
SOLIQUA®, a combination of basal insulin and GLP-1 receptor agonists, has been jointly recommended by the ADA and EASD as an effective strategy for achieving and maintaining glycemic control in type 2 diabetes.
SOLIQUA® distinguishes itself from intensified insulin regimens by offering robust glucose-lowering benefits while minimizing weight gain and reducing the risk of hypoglycemia. Furthermore, SOLIQUA® streamlines the administration of insulin regimens, providing individuals with an easier and more efficient approach to diabetes management.
Reference
- American Diabetes Association. Diabetes Care 2023;46(Suppl. 1):S140–S157 | https://doi.org/10.2337/dc23-S009.
